Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL14762288 | 0.99 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL444587 | 0.98 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| Diethylamine SCHEMBL445593 | 0.93 | HDAC1 (0.67) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| Dimethylamine SCHEMBL15992082 | 0.90 | HDAC1 (0.59) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL4247836 | 0.89 | HDAC1 (0.61) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL443572 | 0.87 | HDAC1 (0.59) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL18597368 | 0.86 | HDAC3 (0.77) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL443222 | 0.85 | HDAC3 (0.80) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL4257526 | 0.85 | HDAC1 (0.57) | HDAC1HDAC2HDAC3HDAC10HDAC8 | |
| SCHEMBL417658 | 0.85 | HDAC3 (0.76) | HDAC1HDAC2HDAC3HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964622-B1 | NOVEL ABEXINOSTAT SALT, ASSOCIATED CRYSTALLINE FORM, PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PHARMACYCLICS LLC (US) | 2017-04-19 | — | — | EP | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| EP-2753322-B1 | DOSAGE REGIMEN OF N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2-YLCARBONYLAMINO]ETHOXY}BENZAMIDE | PHARMACYCLICS INC (US) | 2016-08-03 | — | — | EP | claimed |
| EP-2964622-A1 | NOVEL ABEXINOSTATE SALT, ASSOCIATED CRYSTALLINE FORM, PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Pharmacyclics LLC (US) | 2016-01-13 | — | — | EP | claimed |
| US-20150038513-A1 | ASSOCIATION BETWEEN N-HYDROXY-4-BENZAMIDE AND FOLFOX | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | claimed |
| US-20150024040-A1 | ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE | PHARMACYCLICS LLC | 2015-01-22 | — | — | US | claimed |
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | LES LABORATOIRES SERVIER SAS (FR) | 2014-11-20 | — | — | US | claimed |
| US-8883199-B2 | Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide | LES LABORATOIRES SERVIER (FR) | 2014-11-11 | — | — | US | claimed |
| WO-2014135776-A1 | NOVEL ABEXINOSTATE SALT, ASSOCIATED CRYSTALLINE FORM, PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2014-09-12 | — | — | WO | claimed |
| EP-2755648-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | Pharmacyclics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013093248-A1 | NOVEL COMBINATIONS CONTAINING N-HYDROXY-4-(2-[3-(N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO]ETHOXY)BENZAMIDE IN NASOPHARYNGEAL CARCINOMA | LES LABORATOIRES SERVIER (FR) | 2013-06-27 | — | — | WO | claimed |
| WO-2013039488-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| US-20130064880-A1 | ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE | PHARMACYCLICS, INC. | 2013-03-14 | — | — | US | claimed |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 5/4885HDAC3 7/4885 |
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | HDAC5, HDAC7, HDAC4 | HDAC1 7/4885HDAC2 8/4885HDAC3 11/4885 |
| US-20130064880-A1 | ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE | FOLR2, SLC19A1, FOLR1 | HDAC1 305/4885HDAC2 405/4885HDAC3 673/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | HDAC1 5/4885HDAC2 10/4885HDAC3 2/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885HDAC2 10/4885HDAC3 2/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | HDAC1 1404/4885HDAC2 931/4885HDAC3 884/4885 |
| US-20150038513-A1 | ASSOCIATION BETWEEN N-HYDROXY-4-BENZAMIDE AND FOLFOX | FOLR2, FOLR1, SLC10A2 | HDAC1 344/4885HDAC2 349/4885HDAC3 394/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | HDAC1 1404/4885HDAC2 931/4885HDAC3 884/4885 |
| US-20150024040-A1 | ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE | FOLR2, SLC19A1, FOLR1 | HDAC1 305/4885HDAC2 405/4885HDAC3 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.